VANCOUVER, British Columbia, May 03, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of non-hallucinogenic LSD-based therapeutics for mental disorders, today announced that the Company intends to complete a Non-Brokered Private Placement offering (the “Private Placement”) of up to $500,000.

不列颠哥伦比亚省温哥华，2024年5月3日（环球通讯社）--BetterLife Pharma Inc.（“BetterLife”或“公司”）（CSE:BETR/OTCQB:BETRF/FRA:NPAU），一家新兴的生物技术公司，专注于开发和商业化非致幻剂LSD为基础的精神障碍治疗药物，今天宣布该公司计划完成一项高达50万美元的非经纪私募发行（“私募”）。

The Company intends to use the proceeds for the advancement of its lead compound BETR-001, a non-hallucinogenic derivative of LSD (lysergic acid diethylamide), and general working capital purposes. The Private Placement will be issued in units, pursuant to the offering, with each unit comprised of one common share and one common share purchase warrant having a term of two years from the closing date of the offering.

该公司打算将收益用于推进其先导化合物BETR-001（一种LSD（麦角酸二乙酰胺）的非致幻剂衍生物）和一般营运资金用途。根据本次发行，本次私募将以单位发行，每个单位由一份普通股和一份普通股认购权证组成，自本次发行结束之日起两年。

The close will be announced as soon as it has completed. About BetterLife Pharma BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non- controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered.

一旦结束，将立即宣布结束。关于BetterLife Pharma BetterLife Pharma Inc.是一家新兴的生物技术公司，主要致力于开发和商业化两种化合物BETR-001和BETR-002，用于治疗神经精神疾病和神经系统疾病。BETR-001正在进行临床前和IND研究，是一种非致幻剂和非控制LSD衍生物，正在开发中，它的独特之处在于它不受管制，因此可以自我管理。

BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders. BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark.

BetterLife的BETR-001合成专利消除了监管障碍，其组成和使用方法的待决专利涵盖了重度抑郁症，焦虑症和神经性疼痛以及其他神经精神和神经疾病的治疗。BETR-002正在进行临床前和IND研究，它基于和厚朴酚，厚朴树皮的活性抗焦虑成分。

BetterLife’s pending method.

BetterLife的待定方法。